Objectives: To conduct a systematic review of literature in on epidemiology and economic studies for patients diagnosed with Non-Psychotic Major Depressive Disorder (MDD). MethOds: The initial search strategy was developed in the PubMed/Medline database, and was then translated for the Cochrane and Embase database searches. Search strings for epidemiology and economics studies for MDD were constructed using varied approaches that included the use of MeSH terms, as well as keywords that would afford the best retrieval. Search statements were then combined to produce a final search set. Additional parameters were placed on the final search strategy to limit the retrieval to articles written in English, involving human subjects and published between 2000 and 2010. Results: Our search revealed 289 articles for epidemiology and 200 articles for economic studies on MDD from PubMed/Medline/Embase/Cochrane databases. After removing duplicates and non-relevant articles, 17 for epidemiology and 26 for economic studies were included in the final analysis. Fifteen studies on epidemiology were focused on MDD prevalence, one study was on cumulative incidence. Prevalence estimates were higher for lifetime than past year and ranged between 3.1% and 26.6% for lifetime prevalence and between 1.5% and 11.7% for past-year prevalence. Two studies examined burden of illness, one study budgetary impact of MDD, 14 studies examined cost effectiveness of MDD treatments, 3 studies examined cost utility analysis and 6 other studies examined retrospective claims analysis. cOnclusiOns: MDD prevalence was higher in the lifetime estimates, when compared to the estimates reflecting shorter time frames, although there appeared to be greater variability in the lifetime estimates. Overall, the cost of treating MDD varied with type of study, study time frame, study perspective, the year in which the costs were calculated, and the pharmacotherapy prescribed.
Objectives: To perform a systematic review of literature in peer-reviewed journals on clinical biomarkers, correlates and treatment efficacy in clinical studies on patients diagnosed with Non-Psychotic Major Depressive Disorder (MDD). MethOds: The initial search strategy was developed in the PubMed/Medline database and was then translated for the Cochrane and Embase database searches. Search strings for biomarkers, correlates and treatment efficacy in patients with MDD were constructed using varied approaches that included the use of MeSH terms, as well as keywords that would afford the best retrieval. Also included were search terms that used an asterisk as a wildcard applied to a word stem. Search statements were then combined to produce a final search set. Additional parameters were placed on the final search strategy to limit the retrieval to articles written in English, involving human subjects and published between 2000 and 2010. Results: The initial search revealed 871 articles from PubMed/Medline/Embase/Cochrane databases. After removing duplicates and non-relevant articles, the final articles that were included in the review were 131. Forty-eight studies examined biomarkers and primarily focused on the relationship between biomarkers and MDD treatment response. Only 29 of the 48 studies found a significant association between a biomarker and treatment response. Twenty-nine studies examined MDD correlates such as comorbidity or demographic variables. A poorer response to treatment was found for those patients who experienced comorbid anxiety, irrespective of the type of treatment. Fifty-four studies focused on treatment efficacy and are divided into 3 groups: SSRIs only, SNRIs only, and a comparison across SSRIs, SNRIs, and bupropion. Overall, the SSRIs showed comparable efficacy when compared to each other or placebo. cOnclusiOns: Most of the biomarker studies examined associations between the serotonin transporter and response to various MDD treatments. The majority of efficacy studies found that the treatments that are within the class had comparable efficacy.
MentAl HeAltH -Cost studies

PMH6 tHe iMPACt of AntiPsyCHotiCs PolyPHArMACy on HeAltH CAre Costs of PeoPle witH MentAl disorders in são PAulo City, BrAzil
Razzouk D. , Sousa A. , Oliveira G. G. , Cardoso A. , Mari J. J.
Universidade Federal de Sao Paulo, SAO PAULO, Brazil
Objectives: Antipsychotics polypharmacy (AP) has been associated with more adverse drug effects, higher treatment costs, worse clinical outcomes and sudden death. Though, the frequency of such practice may reach 50 % in some clinical settings. The aims of this study were to estimate AP costs and its influence on the direct costs of health care package in a sample of people with mental disorders in São Paulo city, Brazil. MethOds: We used a bottom-up approach for the estimation of direct costs according to public health service provider perspective. Direct costs included costs with accomodation (residential service), inpatient, outpatient and emergency services and treatment received in the previous month, in 147 subjects with mental disorders living in twenty residential services during the year 2011. We evaluated quality of life, social behavior problems, psychiatric diagnosis, severity of symptoms, sociodemographics characteristics and pattern of health service use. Results: AP was found in 38% of the sample and it was not related with gender, age, severity of psychiatric symptoms, quality of life and social behavior problems. Antipsychotics monotherapy costs were related with the type of antipsychotic: Atypical antipsychot-vant articles, the final articles that were considered for review were 82 for treatment response and 13 for risk factors. Fifty-one studies examined non-genetic factors, serotonin-related genetic factors and variety of genes and polymorphism biomarkers to determine their association with MDD treatment response. Thirtyone studies focused on variables that were found to be associated with some aspect of MDD and their impact on treatment response and include: comorbidity (n= 12), demographic and socioeconomic (n= 6), and depression-related (n= 13) variables. Thirteen studies examined the risk factors for MDD. Of these, 2 studies focused on the role of biomarkers in MDD risk. And, 11 studies focused on variables that were found to be associated with some aspect of MDD and their impact on MDD risk, and focused on comorbidity (n= 5), demographic and socioeconomic (n= 2), depression-related (n= 3), and environmental variables (n= 1). cOnclusiOns: The majority of the biomarker studies examined associations between the serotonin transporter, genes and polymorphisms in response to various MDD treatments. With respect to correlate studies, younger age of MDD onset, as well as family history of mood disorders, were both associated with a longer duration of MDD illness. Objectives: This research uses propensity score methods to identify the relationship between amount of treatment and treatment outcome for adolescents with psychoactive substance use disorder (PSUD). The objective is to describe the dose response relationship in terms relevant in economic evaluation. Outcomes studies in this population show that longer treatment leads to more positive outcomes. The standard for residential programs is a minimum of 21 days of treatment and ideally up to 90 days. MethOds: The subjects are 377 adolescents who successfully completed primary treatment from 2004-2010. All were placed at ASAM level III.5 (Clinically-Managed, Medium/High Intensity Residential). The data are from treatment records and a 234-item questionnaire. The questionnaire responses were matched to variables in treatment records creating a rich source of pre-treatment characteristics. This research operationalizes dose with four one-month categories (1 dose= 1 month) to capture nonlinearities between service use and outcomes. The outcome is three-month post-treatment drug/alcohol abstinence. The categories were fairly even and captured 92% of variation in dose. The first stage of statistical analysis used multinomial logistic regression to predict dosage with pre-treatment variables while adjusting for characteristics influencing both dose and treatment outcome. Propensity scores were then created for each dosage category. The dose response relationship was assessed using a binomial logistic regression including the four dose categories as dummy variables (lowest dose category as reference). Results: The overall relationship between dose and outcome was significant (p= 0.01) as were outcome improvements over the four doses. Improvements were significant (p≤ 0.01) decreasing as dose increased-Exp.(B) was1.204 (1.2 times more likely to abstain) for one month, 1.532 two months, 1.643 three months, and 1.794 for four months (% correctly classified= 94.2; -2LL= 44.712; Cox and Snell R 2 = 0.475.) cOnclusiOns: This research shows a significant dose response relationship between treatment length and treatment outcome with response diminishing on the margin. Objectives: To compare treatment outcomes in patients with major depressive disorder (MDD) treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) for up to 6 months in a naturalistic setting in Mexico. MethOds: Data in this post hoc analysis were taken from a 6-month prospective, non-interventional, observational study that included a total of 1,549 MDD patients without sexual dysfunction in twelve countries (N= 591 in Mexico). Depression severity was measured using the Clinical Global Impression (CGI) and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR 16 ). Pain was measured using the pain related items of the Somatic Symptom Inventory (SSI), and quality of life (QoL) was measured using the EQ-5D instrument with the UK population tariff and the EQ-VAS. Probabilities of initiating duloxetine (vs. SSRIs), expressed as propensity scores, were first constructed using logistic regression. Mixed effects modelling with repeated measures (MMRM) analysis was then used to compare treatment effectiveness and QoL between the duloxetine (N= 168) and SSRI (N= 413) groups, controlling for the propensity scores and other patient characteristics. Results: The severity of depression was comparable between the two groups at baseline. Duloxetine-treated patients, however, had a higher level of pain severity and a lower level of QoL (EQ-5D) than SSRI-treated patients at baseline (p≤ 0.001). Both descriptive and MMRM regression analyses showed that patients treated with duloxetine had better outcomes during follow-up, compared with patients treated with SSRIs. At 6 months, duloxetine-treated patients had lower levels of CGI (2.25 vs. 2.52, p= 0.005), QIDS-SR 16 (3.95 vs. 5.35, p< 0.001), and SSI-pain related (8.52 vs. 9.64, p< 0.001), and higher levels of EQ-5D (0.92 vs. 0.87, p< 0.001) and EQ-VAS (64.62 vs. 57.63, p= 0.006) (MMRM results). cOnclusiOns: Duloxetine-treated patients had better 6-months outcomes in terms of depression severity, pain and QoL, compared with SSRI-treated patients.
PMH2 lengtH of stAy And outCoMes for AdolesCents treAted for suBstAnCe use disorder: An AnAlysis of dose resPose using ProPensity sCores
PMH3
CliniCAl outCoMes of PAtients witH MAjor dePressive disorder treAted witH eitHer duloxetine or seleCtive serotonin reuPtAke inHiBitors in MexiCo
ance with paliperidone palmitate that is related to less relapses, a better quality of life and reduced hospitalization costs.
MentAl HeAltH -Patient-reported outcomes & Patient Preference studies
PMH10 needs AssessMent of PAtients treAted in CoMMunity PsyCHosoCiAl Centers in são PAulo, BrAzil
Nascimento A. 1 , Velasco T. M. 2 , Oliveira M. S. C. 1 1 Faculdade de Ciências Medicas da Santa Casa de São Paulo, São Paulo, Brazil, 2 Hospital Alemão Oswaldo Cruz, São Paulo, Brazil Objectives: To describe the needs of patients treated at community psychosocial centers in Sao Paulo, Brazil. MethOds: Cross-sectional study with 373 patients who were attending psychosocial care activities at least three times per week in community psychosocial centers, during 2007-2008. Needs were assessed using the "Camberwell Assessment of Need" (CAN). Psychotic symptoms were assessed using the "Positive and Negative Symptom Schedule" (PANSS). Results: Mean age of patients was 40.0 years (standard deviation, SD = 12.6 years); 57.6% were male, 57.9% had fundamental education, 40.5% have schizophrenia, 15.9% have worked during last 12 months and 14.7% were living alone. Median time attending in community psychosocial centers was two years (range of 15 days to 30 years) and mean number of weekly therapeutic activities was 3.6 (SD = 2.3). The mean score for the total number of needs was 7.1 (SD = 2.8), with a range of 0 to 15 (maximum = 22). Basic needs were reported by 38 (10.2%) patients; at least one social need was reported by 90.9%. At least one functioning need was reported by 94.4% patients; 85.5% have at least one health need; 86.3% have at least one service need. Women showed higher number of needs than men (p = 0.02) and educational until fundamental level was also associated with more needs (p = 0.02). We did not observe associations between weekly activities, unemployment, age, diagnosis and number of needs. Patients with higher PANSS scores showed more needs (p < 0.001). cOnclusiOns: We observed higher number of needs than in studies conducted in Europe, in all conceptual domains assessed by CAN. Many patients showed needs related to health and services, despite the time that they were attending in community psychosocial centers. Patients' needs should take in account in order to improve the quality of care offered in mental health services.
MentAl HeAltH -Health Care use & Policy studies PMH11 CliniCAl PrACtiCe guideline MAjor dePressive disorder for generAl PrACtitioners
Kongsuk T.
Prasrimahabhodi Psychiatric Hospital, Ubon Ratchathani, Thailand
Objectives: To develop the clinical practice guideline major depressive disorder for general practitioners in primary and secondary health care setting included the diagnosis, differential diagnosis, severity classification and medical treatments. MethOds: A list of 13 key elements of a CPG development process were developed that consisted of 1) setting the review teams; 2) determining the problems; 3) determining health outcomes;4) evidence based literature review; 5) meeting to draft the CPG; 6) formulating draft of CPG; 7) apprising the content of CPG by experts; 8) trail phase; 9) evaluating for trail phase; 10) developing the curricular for CPG training; 11) preparing for CPG training; 12) evaluating; and 13) improving the CPG related with evaluated results. Results: There were 3 main processes in clinical practice guideline major depressive disorder for general practitioners in primary and secondary health care setting (CPG-MDD-GP) which were 1) Assessment of major depressive disorder (clinical assessment using 9Q screening tool and DSM-TR diagnostic criteria, differential diagnosis, diagnosis for major depressive disorder and coding of diagnosis); 2) Management of major depressive disorder; and 3) Management of hospitalized patients. General practitioners were satisfied with the CPG-MDD-GP in trial phase. A total of 416 general practitioners in all provinces were trained to use the CPG-MDD-GP then they would be followed and evaluated. Psychiatrists in psychiatric hospitals/ institutes would be available for consultation from the general practitioners. cOnclusiOns: The CPG-MDD-GP should be distributed to all general practitioners in primary and secondary health care setting. Next step, it would be useful for developing the CPG for MDD in the tertiary health care setting. Objectives: To identify and describe published articles dealing with issues of mental health in pregnancy from Latin American counties MethOds: Medline, Embase and LILACS databases were searched for published studies originating from Latin America regarding mental health issues in pregnancy. Search terms included the names of all countries in the United States Census Bureau International Database + mental health + pregnancy. We included all research and review articles dealing with pregnancy and/or lactation, epidemiology of mental disorders, prevention or treatment of mental disorders, outcomes assessment, and counseling/drug information dissemination. Excluded were papers dealing exlusively with postpartum depression, HIV transmission, induction of abortion, in vitro fertilization, contraception or the use of alcohol or drugs of abuse. Data were analyzed descriptively. Results: The search identified 701 studies; 110 (16%) met the criteria. The earliest was published in 1984 and the contribution has increased exponentially [Y= -1E-125*exp(0.1452X), where X is the year; R-squared= 0.97). The majority (n= 80; 73%) consisted of original research and the other 27% were reviews (23 overviews, 3 systematic reviews/metaanalyses, 4 other). Most frequent topics were depression (37%) as well as mixed anxiety/depression (6%), mental health during pregnancy (32%;), psychotropic drug use in pregnancy (13%), suicidality (6%), and quality of life (1%). By country, 58 (53%) were produced by Brazil, followed by Mexico (n= 18, 17%), Chile (n= 10, 9%), Colombia ics costs were 167.4 times higher than typical antipsychotic costs. AP mean monthly costs per person varied with the type of association between antipsychotics: typicalatypical associations costs were U$257.5± U$228.5, while mean costs between two typical antipsychotics were U$4.36 ± U$4.02. Polypharmacy added U$300.00 dolars per person per month to direct costs of health care (excluding accomodation). For each additional antipsychotic associated, it was observed an additional montlhy costs per person of U$87.5 in the total costs of health care package (health services, treatment and accomodation). cOnclusiOns: AP added substantial costs and risks to treatment and to health care costs and quality. This should be taken in account in resource allocation in public policies, especially in low-resources settings.
PMH12
ContriBution of lAtin AMeriCA to MentAl HeAltH in PregnAnCy
PMH7
ModelizACión eConóMiCA del genotiPAdo del CitoCroMo P450 Con el test BrAinCHiP en el trAtAMiento de lA dePresión MAyor Crespo C. , Villacampa A. , Brosa M. Oblikue Consulting, Barcelona, Spain ObjectivOs: BrainChip es un test genético que predice la respuesta al tratamiento farmacológico de la depresión mayor (DM) determinando los polimorfismos de las isoenzimas CYP450. El objetivo ha sido valorar la eficienciade la incorporación del test BrainChip previa a la prescripción farmacológica en DM tras fallo en primera línea. MetOdOlOgíAs: Se desarrolló un modelo de Markov de ciclos bimensuales para cada fármacode una cohorte hipotética depacientes adultos con DM tras fallo en primera línea. La cohorte se adecuó a la distribución del mercado actual y a su modificación tras incorporar BrainChip. Los datos de eficacia (no respuesta, respuesta y remisión) provienen de revisiones de la literatura y el uso de recursos y costes fue adaptado para el análisis inicial a España. Se analizaron los resultados en un horizonte temporal de 1, 3, 5, 7 y 10 años desde la perspectiva del sistema sanitario aplicando un descuento del 3% sobre los efectos y los costes (euros 2011). ResultAdOs: BrainChip mejora la remisión entre un 9,5%-11,7% y la respuesta entre 5,5%-10,2%, alcanzando a los 10 años una respuesta del 72%. Los pacientes con DM mejoran la calidad de vida con BrainChip entre 0,04 y 0,25 años de vida ajustados por calidad. El coste de Brainchip se compensa a los 2 años resultando siempre coste-efectivo a corto plazo y dominante a partir del tercer año, mostrando ahorros de 1399€ /paciente tras 10 años. cOnclusiOnes: BrainChip en DM es dominante, permite prescribir los tratamientos con menos riesgos y costes y más eficacia. El modelo desarrollado permitiría la adaptación del análisis a cualquier país de Latinoamérica utilizando datos de costos locales.
PMH8 Cost effeCtiveness of PAliPeridone PAlMitAte versus risPeridone long-ACting injeCtABle, QuetiAPine And olAnzAPine for tHe treAtMent of PAtients witH sCHizoPHreniA in ColoMBiA
Casallas C. 1 , Ariza J. G. 2 1 Universidad de la Sabana, Bogotá, Colombia, 2 Janssen Cilag, Bogotá, Colombia Objectives: Schizophrenia is a chronic disorder that requires long-term treatment with antipsychotic medication to minimize relapse and provide clinical benefit to patients. For patients with schizophrenia, non-adherence to medication is a risk factor for relapse and re-hospitalization. Long-acting Injectable (LAI) formulations of atypical antipsychotics provide constant medication delivery and the potential for improved adherence. The objective of this study is to assess the cost-effectiveness of paliperidone palmitate (PP) versus risperidone long acting injectable (RLAI), olanzapine (OP) and quetiapine (QP). MethOds: A Markov decision analytic model was developed to simulate multi-episode patients transitioning through different states on monthly basis over a 5 year time horizon from the perspective of the Colombian Health System. Probability of relapse, level of adherence, side effects, utilities and treatment discontinuation were derived from scientific literature. Only direct costs were considered as medications, laboratory tests, relapses and adverse events by using national tariffs and prices from Ministry of Health medication database. Outcomes were measured as relapses rate and Quality Adjusted Life Years (QALY). Discount rate 3%, exchange rate (1 USD = 1,794 COP) and threshold considered 3xPIB per capita (USD 20,066 / QALY). Results: Total costs (USD): PP (13,338), RLAI (12,635), OP (11,481) and QP (13, 247) . Hospitalization relapses costs (USD): PP (3,276), RLAI (3,341), OP (4,881) and QP (6,840). QALY: PP (3.09), RLAI (3.00), OP (2.93) and QP (2.87). Relapses rate: PP (1.35), RLAI (1.38), OP (2.01) and QP (2.81). Incremental Cost Utility Ratios (ICUR: USD / QALY): PP vs. RLAI (4,517), PP vs. OP (6,713) and PP vs. QP (230). cOnclusiOns: Considering a willingness to pay of USD 20,066 per QALY, the incremental cost of PP versus other alternatives could be compensated by its incremental benefits in terms of relapses avoided and QALY gained. From Health Care Provider perspective, PP demonstrates savings in terms of less hospital setting relapsing costs.
PMH9 tHe Cost-effeCtiveness And Cost-utility of PAliPeridone PAlMitAte in tHe treAtMent of sCHizoPHreniA in guAteMAlA
Obando C. A. 1 , Gonzalez L. 2 , Muschett D. 1 1 Janssen, Panama City, Panama, 2 Janssen, Raritan, NJ, USA Objectives: To compare from the Guatemaltecan third payer perspective the costeffectiveness of paliperidone palmitate with oral quetiapine. MethOds: A Markov model was developed to assess the cost-effectiveness and the cost-utility of treatments available for schizophrenia in Guatemala. The model was adjusted to reflect the compliance of the patient and the real world effectiveness of both treatments. A 10 year time horizon was used. All direct medical costs relevant for the third payer were included. Four types of side effects were considered in the model: extrapyramidal symptoms, weight gain, diabetes and tardive dyskinesia. Deterministic and probabilistic sensitivity analyses were performed. Results: Effectiveness outcomes were reported both in QALYs and relapses avoided. The costs were reported in the local currency Quetzales and all cost and outcomes were discounted at 5% per year. Paliperidone palmitate dominated oral quetiapine by being less expensive (14% less) and more effective (44% less relapses and 20% more QALYs). The sensitive analyses confirmed the robustness of the results. cOnclusiOns: Paliperidone palmitate appeared to be a cost-saving treatment option in comparison with oral quetiapine for patients with schizophrenia in Guatemala. The model reflected a better compli-
